In November, Omeros announced the results from the clinical trial showed the drug met co-primary efficacy endpoints with better pupil dilation and pain reduction after surgery.
More Articles on Ophthalmology:
56 Physician-Owned Hospitals to Know
20 Physicians Scattered Throughout 113th Congress
Ophthalmologist on the Move: Dr. Augustus Stern Joins MD’s Bergman Eye Center
